Fibrinogen A alpha-chain associated amyloidosis

Jump to navigation Jump to search

WikiDoc Resources for Fibrinogen A alpha-chain associated amyloidosis

Articles

Most recent articles on Fibrinogen A alpha-chain associated amyloidosis

Most cited articles on Fibrinogen A alpha-chain associated amyloidosis

Review articles on Fibrinogen A alpha-chain associated amyloidosis

Articles on Fibrinogen A alpha-chain associated amyloidosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fibrinogen A alpha-chain associated amyloidosis

Images of Fibrinogen A alpha-chain associated amyloidosis

Photos of Fibrinogen A alpha-chain associated amyloidosis

Podcasts & MP3s on Fibrinogen A alpha-chain associated amyloidosis

Videos on Fibrinogen A alpha-chain associated amyloidosis

Evidence Based Medicine

Cochrane Collaboration on Fibrinogen A alpha-chain associated amyloidosis

Bandolier on Fibrinogen A alpha-chain associated amyloidosis

TRIP on Fibrinogen A alpha-chain associated amyloidosis

Clinical Trials

Ongoing Trials on Fibrinogen A alpha-chain associated amyloidosis at Clinical Trials.gov

Trial results on Fibrinogen A alpha-chain associated amyloidosis

Clinical Trials on Fibrinogen A alpha-chain associated amyloidosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrinogen A alpha-chain associated amyloidosis

NICE Guidance on Fibrinogen A alpha-chain associated amyloidosis

NHS PRODIGY Guidance

FDA on Fibrinogen A alpha-chain associated amyloidosis

CDC on Fibrinogen A alpha-chain associated amyloidosis

Books

Books on Fibrinogen A alpha-chain associated amyloidosis

News

Fibrinogen A alpha-chain associated amyloidosis in the news

Be alerted to news on Fibrinogen A alpha-chain associated amyloidosis

News trends on Fibrinogen A alpha-chain associated amyloidosis

Commentary

Blogs on Fibrinogen A alpha-chain associated amyloidosis

Definitions

Definitions of Fibrinogen A alpha-chain associated amyloidosis

Patient Resources / Community

Patient resources on Fibrinogen A alpha-chain associated amyloidosis

Discussion groups on Fibrinogen A alpha-chain associated amyloidosis

Patient Handouts on Fibrinogen A alpha-chain associated amyloidosis

Directions to Hospitals Treating Fibrinogen A alpha-chain associated amyloidosis

Risk calculators and risk factors for Fibrinogen A alpha-chain associated amyloidosis

Healthcare Provider Resources

Symptoms of Fibrinogen A alpha-chain associated amyloidosis

Causes & Risk Factors for Fibrinogen A alpha-chain associated amyloidosis

Diagnostic studies for Fibrinogen A alpha-chain associated amyloidosis

Treatment of Fibrinogen A alpha-chain associated amyloidosis

Continuing Medical Education (CME)

CME Programs on Fibrinogen A alpha-chain associated amyloidosis

International

Fibrinogen A alpha-chain associated amyloidosis en Espanol

Fibrinogen A alpha-chain associated amyloidosis en Francais

Business

Fibrinogen A alpha-chain associated amyloidosis in the Marketplace

Patents on Fibrinogen A alpha-chain associated amyloidosis

Experimental / Informatics

List of terms related to Fibrinogen A alpha-chain associated amyloidosis

To go back to the Amyloidosis landing page, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Synonyms and Keywords: Fibrinogen amyloidosis

Overview

Fibrinogen A a-chain amyloidosis (AFib) is a systemic disease caused by extracellular deposition of insoluble amyloid fibrils composed of abnormal fibrinogen, arising from autosomal dominant mutations in the gene encoding AFib.

Historical Perspective

Fibrinogen A a-chain amyloidosis (AFib) was first discovered by Merill Benson et al., in 1993.[1]

Classification

Pathophysiology

Causes

Fibrinogen Aα-chain amyloidosis is caused by the extracellular deposition of amyloid fibrils induced by mutations in fibrinogen Aα-chain gene (FGA).[2]

Epidemiology and Demographics

Risk Factors

There are no specific risk factors associated with fibrinogen A alpha-chain amyloidosis.

Screening

There is insufficient evidence to recommend routine screening for Fibrinogen A a-chain amyloidosis.

Natural History, Complications, and Prognosis

Patients with fibrinogen amyloidosis usually develop chronic kidney disease, typically progressing to end-stage renal disease within 5 years of recognition of renal involvement.

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

  • Laboratory findings of fibrinogen A a-chain amyloidosis (AFib) can include derangement in multiple serum markers.
  • This derangement, when present, goes in line with the type of the organ/organ system involved.

Electrocardiogram

X-ray

There are no x-ray findings associated with fibrinogen amyloidosis.

Echocardiography or Ultrasound

  • There are no specific echocardiographic or ultrasound findings associated with fibrinogen A a-chain amyloidosis (AFib).
  • To read more in the case of involvement of the heart, click here.

CT scan

  • There are no specific CT scan findings associated with fibrinogen A a-chain amyloidosis (AFib).
  • To learn about the CT scan findings in the setting of an involved heart, click here.

MRI

  • There are no specific MRI findings associated with fibrinogen A a-chain amyloidosis (AFib).
  • For MRI findings in an involved heart click here.

Other Imaging Findings

  • There are no other imaging findings associated with fibrinogen A a-chain amyloidosis (AFib).

Other Diagnostic Studies

  • There are no other diagnostic studies associated with fibrinogen A a-chain amyloidosis (AFib).

Treatment

Medical Therapy

Fibrinogen production is exclusively hepatic. Isolated renal transplantation as a treatment for renal failure in fibrinogen amyloidosis is of limited value.[10]

Surgery

Surgery is not indicated in the management of fibrinogen A a-chain amyloidosis (AFib).

Primary Prevention

There are no established measures for the primary prevention of fibrinogen A a-chain amyloidosis (AFib).

Secondary Prevention

There are no established measures for the secondary prevention of fibrinogen A a-chain amyloidosis (AFib).

References

  1. Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R (1993). "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain". Nat Genet. 3 (3): 252–5. doi:10.1038/ng0393-252. PMID 8097946.
  2. 2.0 2.1 Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R (1993). "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain". Nat Genet. 3 (3): 252–5. doi:10.1038/ng0393-252. PMID 8097946.
  3. Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G; et al. (2017). "Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein". Kidney Int Rep. 2 (3): 461–469. doi:10.1016/j.ekir.2016.11.005. PMC 5678610. PMID 29142973.
  4. Matsuda M, Sugo T (2001). "Hereditary disorders of fibrinogen". Ann N Y Acad Sci. 936: 65–88. doi:10.1111/j.1749-6632.2001.tb03494.x. PMID 11460526.
  5. Benson MD (2005). "Ostertag revisited: the inherited systemic amyloidoses without neuropathy". Amyloid. 12 (2): 75–87. doi:10.1080/13506120500106925. PMID 16011983.
  6. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH; et al. (2009). "Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis". J Am Soc Nephrol. 20 (2): 444–51. doi:10.1681/ASN.2008060614. PMC 2637055. PMID 19073821.
  7. Ridolfi RL, Bulkley BH, Hutchins GM (1977). "The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients". The American Journal of Medicine. 62 (5): 677–86. PMID 871125. Unknown parameter |month= ignored (help)
  8. Rahman JE, Helou EF, Gelzer-Bell R; et al. (2004). "Noninvasive diagnosis of biopsy-proven cardiac amyloidosis". Journal of the American College of Cardiology. 43 (3): 410–5. doi:10.1016/j.jacc.2003.08.043. PMID 15013123. Unknown parameter |month= ignored (help)
  9. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M (2005). "Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement". The American Journal of Cardiology. 95 (4): 535–7. doi:10.1016/j.amjcard.2004.10.028. PMID 15695149. Unknown parameter |month= ignored (help)
  10. Mousson C, Heyd B, Justrabo E, Rebibou JM, Tanter Y, Miguet JP; et al. (2006). "Successful hepatorenal transplantation in hereditary amyloidosis caused by a frame-shift mutation in fibrinogen Aalpha-chain gene". Am J Transplant. 6 (3): 632–5. doi:10.1111/j.1600-6143.2005.01199.x. PMID 16468976.


Template:WikiDoc Sources